These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 30551856)

  • 1. Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer.
    van den Ende T; Smyth E; Hulshof MCCM; van Laarhoven HWM
    Best Pract Res Clin Gastroenterol; 2018; 36-37():45-52. PubMed ID: 30551856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials.
    Zhao X; Ren Y; Hu Y; Cui N; Wang X; Cui Y
    PLoS One; 2018; 13(8):e0202185. PubMed ID: 30138325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of different available chemotherapy regimens combined with radiotherapy for the neoadjuvant and definitive treatment of esophageal cancer.
    Tomasello G; Ghidini M; Barni S; Passalacqua R; Petrelli F
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):649-660. PubMed ID: 28349718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
    Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
    J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.
    Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Jensen K;
    Cochrane Database Syst Rev; 2013 May; (5):CD008107. PubMed ID: 23728671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Short-term efficacy and safety of the synchronous neoadjuvant chemoradiotherapy with paclitaxel plus carboplatin in stage III adenocarcinoma of esophagogastric junction].
    Ji Y; Peng T; Wang G; Zhang Y; Cao M; Gao Q; Li S
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1019-1024. PubMed ID: 30269322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
    Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Perioperative treatment for resectable esogastric adenocarcinoma].
    Dabout V; de la Fouchardière C; Voron T; André T; Huguet F; Cohen R
    Bull Cancer; 2023 May; 110(5):521-532. PubMed ID: 35965103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on Neoadjuvant Regimens for Patients with Operable Oesophageal/Gastrooesophageal Junction Adenocarcinomas and Squamous Cell Carcinomas.
    Cox SJ; O'Cathail SM; Coles B; Crosby T; Mukherjee S
    Curr Oncol Rep; 2017 Jan; 19(1):7. PubMed ID: 28213876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASO Author Reflections: Neoadjuvant Chemotherapy Combined with Immunotherapy is a Promising Strategy for Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
    Sun X; Lyu J; Yin Y; Tao K
    Ann Surg Oncol; 2024 Nov; 31(12):8179-8180. PubMed ID: 39212861
    [No Abstract]   [Full Text] [Related]  

  • 11. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).
    Hoeppner J; Lordick F; Brunner T; Glatz T; Bronsert P; Röthling N; Schmoor C; Lorenz D; Ell C; Hopt UT; Siewert JR
    BMC Cancer; 2016 Jul; 16():503. PubMed ID: 27435280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction.
    Zhao Q; Li Y; Wang J; Zhang J; Qiao X; Tan B; Tian Y; Shi G; Xu Q; Li R; Liu Y; Yang P
    Am J Med Sci; 2015 Jun; 349(6):472-6. PubMed ID: 25996101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.
    Springfeld C; Wiecha C; Kunzmann R; Heger U; Weichert W; Langer R; Stange A; Blank S; Sisic L; Schmidt T; Lordick F; Jäger D; Grenacher L; Bruckner T; Büchler MW; Ott K
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S905-14. PubMed ID: 26001861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant and adjuvant multimodality therapies in resectable esophagogastric adenocarcinoma.
    Lau DK; Athauda A; Chau I
    Expert Opin Pharmacother; 2021 Aug; 22(11):1429-1441. PubMed ID: 33688789
    [No Abstract]   [Full Text] [Related]  

  • 15. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.
    Ajani JA; Walsh G; Komaki R; Morris J; Swisher SG; Putnam JB; Lynch PM; Wu TT; Smythe R; Vaporciyan A; Faust J; Cohen DS; Nivers R; Roth JA
    Cancer; 2004 Jun; 100(11):2347-54. PubMed ID: 15160337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs).
    Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Nowak K; Kieser M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Schuhmacher C; Urba S; van de Velde C; Walsh TN; Ychou M; Jensen K
    Eur J Surg Oncol; 2017 Aug; 43(8):1550-1558. PubMed ID: 28551325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
    Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
    BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma.
    Okamura A; Watanabe M; Mine S; Kurogochi T; Yamashita K; Hayami M; Imamura Y; Ogura M; Ichimura T; Takahari D; Chin K
    Dis Esophagus; 2017 Sep; 30(9):1-8. PubMed ID: 28859367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of neoadjuvant therapy for esophageal adenocarcinoma.
    Ku GY; Ilson DH
    Surg Oncol Clin N Am; 2009 Jul; 18(3):533-46. PubMed ID: 19500742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies.
    Kim S; Barzi A; Rajdev L
    Semin Oncol; 2018 Jun; 45(3):133-150. PubMed ID: 30262395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.